Though Bangladesh is “on track” to meet most of the Millennium Development Goal (MDG) targets laid out by the U.N., “many female-focused targets, including maternal mortality are lagging far behind,” writes Women’s eNews, adding that “progress has stalled” at 351 deaths per 100,000, “a point far above the 2014 target figure of 144.” The country [...]
No Comments »
Filed under: Women's Health
The European Society for Medical Oncology (ESMO) just released an enhanced and revised set of clinical recommendations designed to help oncologists deliver the best quality care to their patients…
No Comments »
Filed under: Women's Health
Citing growing evidence that nonprescription access does not compromise the safety of the birth control pill, a coalition of women’s health experts is working to gain FDA approval to market an oral contraceptive for nonprescription use, Newsweek reports…
No Comments »
Filed under: Women's Health
The following summarizes selected women’s health related videos. Family Planning Enables Economic Progress: In a video and commentary on the Daily Beast, actress Ashley Judd describes how access to contraception enabled a Tanzanian woman to provide economic stability and educational opportunities for her daughters…
No Comments »
Filed under: Women's Health
The findings of a scientific conference examining the growing body of research and potential health benefits of S-equol were published this month in the Journal of Nutrition…
No Comments »
Filed under: Women's Health
As obesity continues to be a worldwide health risk, one of its “side effects” could include less effective birth control for overweight and obese women who use hormonal contraceptives. Four of seven studies examined in a recent research review comprising 39,531 women suggest that the heaviest women have the highest risk of pregnancy while using [...]
No Comments »
Filed under: Women's Health
WASHINGTON (MedPage Today) — Rosiglitazone (Avandia) should be pulled from the market because of the “serious” cardiovascular risk the diabetes drug poses, which exceeds that of competitor pioglitazone (Actos), FDA staff reviewers again recommended.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — The FDA advisory panel scheduled to meet next week to review the cardiovascular safety of rosiglitazone (Avandia) will have 2,000 pages of briefing documents — including a special report from the Institute of Medicine — to guide members as they decide the future of the drug.
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — Rosiglitazone (Avandia) should be pulled from the market because of the “serious” cardiovascular risk the diabetes drug poses, which exceeds that of competitor pioglitazone (Actos), FDA staff reviewers again recommended.
No Comments »
Filed under: Pharmacy News
Another 21 lots of over-the-counter medications sold by McNeil Consumer Healthcare have been recalled because of the “musty or moldy odor” problem that has dogged the company since last November.
No Comments »
Filed under: Pharmacy News
